Cisplatin: Forty-five Years Later and What We Still Do Not Know about Ototoxicity

ABSTRACT

Cisplatin is a widely used chemotherapy agent that treats various types of malignancies. Over several decades, cisplatin has been integrated into both curative and palliative chemotherapy regimens. Ototoxicity from cisplatin is a dose-limiting side effect. True risk factors for ototoxicity with cisplatin have been difficult to elucidate, but these may include older age, previous hearing loss, concurrent radiation to the ear area, cumulative dose, and dose amount. Agents such as amifostine have been used as chemoprotectants to try to reduce the amount of ototoxicity, but have not had consistent results. As more patients are exposed to cisplatin at higher doses and at younger ages, the true impact of ototoxicity has not been determined. Currently there is no standard of care to screen patients for risk of ototoxicity prior to cisplatin use or to monitor patients for the development of ototoxicity while the patient is receiving cisplatin therapy. This review provides an overview of the current role of cisplatin and the proposed mechanism of ototoxicity and describes the literature for the use of chemoprotectants to try to reduce the incidence of ototoxicity.

KEYWORDS

Cisplatin - ototoxicity - cancer - chemoprotectants

REFERENCES

• 1 Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode.  Nature. 1965;  205 698-699
• 2 Reed E. Cisplatin, carboplatin, and oxaliplatin. In: Chabner B, Longo D, eds. Cancer chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 332-343
• 3 Tsang R Y, Al-Fayea T, Au H J. Cisplatin overdose: toxicities and management.  Drug Saf. 2009;  32 1109-1122
• 4 Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi F P, De Lena M. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.  J Urol. 2000;  164 53-56
• 5 Monk B J, Sill M W, McMeekin D S et al.. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.  J Clin Oncol. 2009;  27 4649-4655
• 6 Minsky B D, Pajak T F, Ginsberg R J et al.. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.  J Clin Oncol. 2002;  20 1167-1174
• 7 Cunningham D, Allum W H, Stenning S P MAGIC Trial Participants et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.  N Engl J Med. 2006;  355 11-20
• 8 Cooper J S, Pajak T F, Forastiere A A Radiation Therapy Oncology Group 9501/Intergroup et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.  N Engl J Med. 2004;  350 1937-1944
• 9 Winton T, Livingston R, Johnson D National Cancer Institute of Canada Clinical Trials Group et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.  N Engl J Med. 2005;  352 2589-2597
• 10 Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon J P, Vansteenkiste J. International Adjuvant Lung Cancer Trial Collaborative Group . Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.  N Engl J Med. 2004;  350 351-360
• 11 Fossella F, Pereira J R, von Pawel J et al.. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.  J Clin Oncol. 2003;  21 3016-3024
• 12 Albain K S, Crowley J J, Turrisi III A T et al.. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.  J Clin Oncol. 2002;  20 3454-3460
• 13 Lewis I J, Nooij M A, Whelan J MRC BO06 and EORTC 80931 collaborators et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.  J Natl Cancer Inst. 2007;  99 112-128
• 14 Turrisi III A T, Kim K, Blum R et al.. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.  N Engl J Med. 1999;  340 265-271
• 15 Saxman S B, Finch D, Gonin R, Einhorn L H. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.  J Clin Oncol. 1998;  16 702-706
• 16 Nichols C R, Catalano P J, Crawford E D, Vogelzang N J, Einhorn L H, Loehrer P J. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.  J Clin Oncol. 1998;  16 1287-1293
• 17 Zuur C L, Simis Y J, Lansdaal P E et al.. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.  J Clin Oncol. 2007;  25 3759-3765
• 18 Rades D, Fehlauer F, Sheikh-Sarraf M et al.. Toxicity of two cisplatin-based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer.  Head Neck. 2008;  30 235-241
• 19 Rybak L P. Mechanisms of cisplatin ototoxicity and progress in otoprotection.  Curr Opin Otolaryngol Head Neck Surg. 2007;  15 364-369
• 20 Hellberg V, Wallin I, Eriksson S et al.. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity.  J Natl Cancer Inst. 2009;  101 37-47
• 21 Oldenburg J, Kraggerud S M, Cvancarova M, Lothe R A, Fossa S D. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.  J Clin Oncol. 2007;  25 708-714
• 22 Ross C JD, Katzov-Eckert H, Dubé M P CPNDS Consortium et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.  Nat Genet. 2009;  41 1345-1349
• 23 Rademaker-Lakhai J M, Crul M, Zuur L et al.. Relationship between cisplatin administration and the development of ototoxicity.  J Clin Oncol. 2006;  24 918-924
• 24 Waters G S, Ahmad M, Katsarkas A, Stanimir G, McKay J. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.  Ear Hear. 1991;  12 91-102
• 25 Schaefer S D, Post J D, Close L G, Wright C G. Ototoxicity of low- and moderate-dose cisplatin.  Cancer. 1985;  56 1934-1939
• 26 Nagy J L, Adelstein D J, Newman C W, Rybicki L A, Rice T W, Lavertu P. Cisplatin ototoxicity: the importance of baseline audiometry.  Am J Clin Oncol. 1999;  22 305-308